<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="preprint">
<?all-math-mml yes?>
<?use-mml?>
<?origin ukpmcpa?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">bioRxiv</journal-id>
<journal-title-group>
<journal-title>bioRxiv : the preprint server for biology</journal-title>
</journal-title-group>
<issn pub-type="ppub"/>
</journal-meta>
<article-meta>
<article-id pub-id-type="manuscript">EMS141105</article-id>
<article-id pub-id-type="doi">10.1101/2021.12.08.471707</article-id>
<article-id pub-id-type="archive">PPR430746</article-id>
<article-version article-version-type="publisher-id">2</article-version>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Delta breakthrough infections elicit potent, broad and durable neutralizing antibody responses</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Walls</surname>
<given-names>Alexandra C.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="corresp" rid="CR1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sprouse</surname>
<given-names>Kaitlin R.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Joshi</surname>
<given-names>Anshu</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bowen</surname>
<given-names>John E.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Franko</surname>
<given-names>Nicholas</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Navarro</surname>
<given-names>Mary Jane</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Stewart</surname>
<given-names>Cameron</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>McCallum</surname>
<given-names>Matthew</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Goecker</surname>
<given-names>Erin A.</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Degli-Angeli</surname>
<given-names>Emily J.</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Logue</surname>
<given-names>Jenni</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Greninger</surname>
<given-names>Alex</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chu</surname>
<given-names>Helen</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Veesler</surname>
<given-names>David</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="corresp" rid="CR1">*</xref>
</contrib>
<aff id="A1">
<label>1</label>Department of Biochemistry, University of Washington, Seattle, WA 98195, USA</aff>
<aff id="A2">
<label>2</label>Howard Hughes Medical Institute, University of Washington, Seattle, WA 98195, USA</aff>
<aff id="A3">
<label>3</label>Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA 98195, USA</aff>
<aff id="A4">
<label>4</label>Department of Laboratory Medicine and Pathology, University of Washington School of Medicine, Seattle, WA, USA</aff>
</contrib-group>
<author-notes>
<corresp id="CR1">
<label>*</label>Correspondence <email>acwalls@uw.edu</email>, <email>dveesler@uw.edu</email>
</corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>07</day>
<month>02</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="preprint">
<day>13</day>
<month>12</month>
<year>2021</year>
</pub-date>
<permissions>
<ali:free_to_read/>
<license>
<ali:license_ref>https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
<license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">CC BY-NC-ND 4.0 International license</ext-link>.</license-p>
</license>
</permissions>
<abstract>
<p id="P1">The SARS-CoV-2 Delta variant is currently responsible for most infections worldwide, including among fully vaccinated individuals. Although these latter infections are associated with milder COVID-19 disease relative to unvaccinated subjects, the specificity and durability of antibody responses elicited by Delta breakthrough cases remain unknown. Here, we demonstrate that breakthrough infections induce serum binding and neutralizing antibody responses that are markedly more potent, durable and resilient to spike mutations observed in variants of concern than those observed in subjects who were infected only or received only two doses of COVID-19 vaccine. However, wee show that Delta breakthrough cases, subjects who were vaccinated after SARS-CoV-2 infection and individuals vaccinated three times (without infection) have serum neutralizing activity of comparable magnitude and breadth indicate that multiple types of exposure or increased number of exposures to SARS-CoV-2 antigen(s) enhance spike-specific antibody responses. Neutralization of the genetically divergent SARS-CoV, however, was moderate with all four cohorts examined, except after four exposures to the SARS-CoV-2 spike, underscoring the importance of developing vaccines eliciting broad sarbecovirus immunity for pandemic preparedness.</p>
</abstract>
</article-meta>
</front>
<body>
<p id="P2">The SARS-CoV-2 Delta (B.1.617.2) variant of concern emerged at the end of 2020 and became dominant globally by mid-2021. Mutations in the spike (S) glycoprotein (<xref ref-type="bibr" rid="R15">Johnson et al., 2021</xref>; <xref ref-type="bibr" rid="R46">Walls et al., 2020a</xref>; <xref ref-type="bibr" rid="R53">Wrapp et al., 2020</xref>) and in the nucleoprotein (N) have been suggested to account for its enhanced transmissibility, replication kinetics and viral loads in oropharyngeal and nose-throat swabs of infected individuals relative to the ancestral Wuhan-Hu-1 virus and other variants (<xref ref-type="bibr" rid="R23">Li et al., 2021</xref>; <xref ref-type="bibr" rid="R24">Liu et al., 2021</xref>; <xref ref-type="bibr" rid="R30">Mlcochova et al., 2021</xref>; <xref ref-type="bibr" rid="R38">Saito et al., 2021</xref>; <xref ref-type="bibr" rid="R43">Syed et al., 2021</xref>). Moreover, multiple S mutations in the N-terminal domain and receptor-binding domain have been shown to promote immune evasion (<xref ref-type="bibr" rid="R27">McCallum et al., 2021a</xref>, <xref ref-type="bibr" rid="R28">2021b</xref>; <xref ref-type="bibr" rid="R30">Mlcochova et al., 2021</xref>; <xref ref-type="bibr" rid="R42">Suryadevara et al., 2021</xref>; <xref ref-type="bibr" rid="R54">Ying et al., 2021</xref>). These characteristics combined with waning of serum neutralizing antibody titers over time in vaccinated individuals has resulted in Delta breakthrough infections that are usually associated with much milder symptoms than infection of unvaccinated individuals (<xref ref-type="bibr" rid="R22">Levine-Tiefenbrun et al., 2021</xref>; <xref ref-type="bibr" rid="R30">Mlcochova et al., 2021</xref>).</p>
<p id="P3">Understanding the magnitude and breadth of immune responses following a breakthrough infection is key to guiding vaccination policies and pandemic preparedness efforts (<xref ref-type="bibr" rid="R9">Collier et al., 2021</xref>). Serum neutralizing antibody titers represent the current best correlate of protection against SARS-CoV-2 in animal challenge studies (<xref ref-type="bibr" rid="R1">Arunachalam et al., 2021</xref>; <xref ref-type="bibr" rid="R4">Case et al., 2020a</xref>; <xref ref-type="bibr" rid="R10">Corbett et al., 2021</xref>; <xref ref-type="bibr" rid="R13">Hassan et al., 2021</xref>; <xref ref-type="bibr" rid="R18">Khoury et al., 2021</xref>; <xref ref-type="bibr" rid="R29">McMahan et al., 2021</xref>; <xref ref-type="bibr" rid="R52">Winkler et al., 2020</xref>) and multiple clinical trials have shown the benefits of therapeutic administration of monoclonal antibodies in humans (<xref ref-type="bibr" rid="R11">Corti et al., 2021</xref>). Furthermore, serum neutralizing antibodies are used in ongoing comparative clinical trials as key success metrics for the next generation of vaccines (e.g., NCT05007951 and NCT04864561 comparing GBP510 and VLA2001 to AZD1222, respectively). To understand whether the order of infection and/or vaccination as well as repeated exposures alter the specificity, magnitude, and breadth of antibody responses, we followed and compared serum antibodies in individuals who were vaccinated, who were previously infected and then vaccinated, or who were first vaccinated and then infected with the SARS-CoV-2 Delta variant.</p>
<p id="P4">We compared serum binding titers following infection, vaccination, or both in groups of ~15 individuals enrolled through the longitudinal cohort study, HAARVI, at the University of Washington in Seattle (<xref ref-type="supplementary-material" rid="SD1">Table S1-S4</xref>). Individuals in the Delta breakthrough group (n=1 with Johnson and Johnson Ad26.COV2.S, n=2 with Moderna mRNA-1273, n=13 with Pfizer Cominarty), in the infected then vaccinated (infected/vaccinated) cohort (n=1 with Johnson and Johnson Ad26.COV2.S, n=3 with Moderna mRNA-1273, n=11 with Pfizer Cominarty), and in the vaccinated-only group (n=3 with Moderna mRNA-1273, n=12 with Pfizer Cominarty) (<xref ref-type="supplementary-material" rid="SD1">Table S1-S3</xref>) were compared to human convalescent sera (HCS) which were collected prior to October 2020 in Washington State (all samples were obtained prior to July 2020 except one which was drawn in September 2020), indicating these infections were not with any variants of concern (VOC) (according to outbreaks.info) (<xref ref-type="supplementary-material" rid="SD1">Table S4</xref>). Eight individuals from the infected/vaccinated or vaccinated-only groups received a third vaccine dose (i.e. booster, designated 3X). All these samples were compared to SARS-CoV-2 naive individuals who had blood drawn prior to vaccination (<xref ref-type="supplementary-material" rid="SD1">Table S5</xref>) as confirmed by the lack of SARS-CoV-2 nucleocapsid (N) reactivity using the Roche Elecsys anti-N immuno assay (only convalescent samples were positive) (<xref ref-type="supplementary-material" rid="SD1">Table S1-S5</xref>).</p>
<p id="P5">Serum IgG, IgA, and IgM binding titers were evaluated using ELISAs with the SARS-CoV-2 Hexapro S antigen (<xref ref-type="bibr" rid="R14">Hsieh et al., 2020</xref>). The cohorts were followed longitudinally for up to 6 months/180 days after initial blood draws to evaluate differences in durability of antibody responses. Responses were highest amongst individuals who were exposed to SARS-CoV-2 S three or four times through vaccination-only or a combination of infection and vaccination. The magnitude of IgG responses for vaccinated individuals who experienced a breakthrough infection with the Delta variant had geometric mean titers (GMT) of 2.1×10<sup>5</sup> and 8.8×10<sup>4</sup> 30 days and 60 days after positive PCR test, respectively (<xref ref-type="fig" rid="F1">Figure 1A</xref> and <xref ref-type="supplementary-material" rid="SD1">Figure S1</xref>). Infected/vaccinated individuals had binding GMTs of 1.3×10<sup>5</sup>, 5.8×10<sup>4</sup> and 7.8×10<sup>4</sup> at 10 days, 112 days and 180 days after the second dose and 4.6×10<sup>5</sup> 10 days after a third vaccine shot (<xref ref-type="fig" rid="F1">Figure 1A</xref> and <xref ref-type="supplementary-material" rid="SD1">Figure S1</xref>), corresponding to a 3.6 fold increase when comparing titers 10 days after the second and third vaccination. Vaccinated-only individuals had binding GMTs of 1.7×10<sup>4</sup>, 9.5×10<sup>3</sup> and 5.4×10<sup>3</sup> at 10 days, 112 days and 180 days after receiving a second vaccine dose which rose to 4.6×10<sup>5</sup> 10 days following a boost with a third vaccination (<xref ref-type="fig" rid="F1">Figure 1A</xref> and <xref ref-type="supplementary-material" rid="SD1">Figure S1</xref>), amounting to a 26 fold increase between the peak titers after the second and third vaccination. We determined GMTs of 4.2×10<sup>2</sup> for infected individuals that were not vaccinated and 8.8×10<sup>1</sup> (just above the limit of detection) for SARS-CoV-2 naive individuals, as confirmed by the lack of reactivity in a SARS-CoV-2 N immunoassay (<xref ref-type="fig" rid="F1">Figure 1A</xref>, <xref ref-type="supplementary-material" rid="SD1">Figure S1, Table S5</xref>). These data suggest that repeated exposures through vaccination, infection or a combination of both induce potent and durable polyclonal plasma antibody binding titers. Furthermore, we observed a greater durability of binding GMTs over 180 days for the infected/vaccinated relative to the vaccinated-only (two doses) cohorts, which could result from increased number of exposures or due to actual infection.</p>
<p id="P6">We determined peak S-specific IgA binding GMTs of 1.1×10<sup>4</sup> for Delta breakthrough cases, 2.3×10<sup>4</sup> for infected/vaccinated individuals, 2.2×10<sup>3</sup> for vaccinated-only individuals and 2.3×10<sup>2</sup> for HCS (<xref ref-type="fig" rid="F1">Figure 1B</xref> and <xref ref-type="supplementary-material" rid="SD1">Figure S2</xref>), following a magnitude trend similar to IgG binding titers. Conversely, IgM binding titers were roughly an order of magnitude higher for HCS (GMT of 7×10<sup>2</sup>) relative to other cohorts (<xref ref-type="fig" rid="F1">Figure 1C</xref>), presumably as a result of extensive immunoglobulin class switching and affinity maturation occurring for the latter cases, mirroring findings made with memory B cells in vaccinated individuals (<xref ref-type="bibr" rid="R7">Cho et al., 2021</xref>). Collectively, these data indicate that breakthrough infections, vaccination following infection and triple vaccination trigger similarly robust anamnestic responses.</p>
<p id="P7">To assess how vaccination and infection affect the breadth of binding antibody responses, we performed ELISAs using prefusion diproline-stabilized (2P) SARS-CoV S as antigen (<xref ref-type="bibr" rid="R19">Kirchdoerfer et al., 2018</xref>; <xref ref-type="bibr" rid="R32">Pallesen et al., 2017</xref>). At 30 days post infection or 10 days post second vaccination (2X), we determined GMTs of 1.9×10<sup>3</sup> for Delta breakthrough patients, 7.7×10<sup>3</sup> for infected/vaccinated individuals, and 9.3×10<sup>2</sup> for vaccinated-only individuals (<xref ref-type="fig" rid="F1">Figure 1D</xref>). Upon receiving a booster immunization, both infected/vaccinated (3X) and vaccinated-only (3X) SARS-CoV S-specific responses increased to 1.2×10<sup>4</sup> (1.5 fold increase from 2X) and 8.9×10<sup>3</sup> (9.5 fold increase from 2X), respectively. We observed the lowest SARS-CoV S responses for HCS (6.3×10<sup>1</sup>), which are subjects who had only been infected once by SARS-CoV-2, and for naive individuals (limit of detection), who were never exposed. These results suggest that antibody cross-reactivity within the sarbecovirus subgenus improves markedly with repeated exposures to SARS-CoV-2 S (<xref ref-type="fig" rid="F1">Figure 1D</xref>). We also investigated antibody cross-reactivity beyond the sarbecovirus subgenus using the prefusion-stabilized S trimers of the common-cold causing embecoviruses OC43 (<xref ref-type="bibr" rid="R45">Tortorici et al., 2019</xref>) and HKU1 as ELISA antigens. We determined GMTs of 3.6×10<sup>2</sup> (OC43 S) and 2.8×10<sup>2</sup> (HKU1 S) for Delta breakthrough, 7.2×10<sup>2</sup> (OC43 S) and 7.6×10<sup>2</sup> (HKU1 S) for 2X infected/vaccinated, 1.2×10<sup>3</sup> (OC43 S) and 1.1×10<sup>3</sup> (HKU1 S) for 3X infected/vaccinated, 5.7×10<sup>2</sup> (OC43 S) and 5.5×10<sup>2</sup> (HKU1 S) for 2X vaccinated-only, and 5.8×10<sup>2</sup> (OC43 S) and 5.1×10<sup>2</sup> (HKU1 S) for 3X vaccinated-only cohorts (<xref ref-type="fig" rid="F1">Figure 1E-F</xref>). Individuals who were infected with SARS-CoV-2 had GMTs of 9.2×10<sup>2</sup> (OC43 S) and 6.7×10<sup>2</sup> (HKU1 S) and those who were SARS-CoV-2 naive had GMTs of 3.1×10<sup>2</sup> (OC43 S) and 1.7×10<sup>2</sup> (HKU1 S) (<xref ref-type="fig" rid="F1">Figure 1E-F</xref>). These findings show that exposure to SARS-CoV-2 S does not enhance emebecovirus cross-reactive antibody responses even compared to SARS-CoV-2 naive individuals, who might have been previously exposed to seasonal coronaviruses.</p>
<p id="P8">To understand the magnitude and durability of neutralizing antibody responses among the different groups, we determined serum neutralizing activity for all samples obtained longitudinally using vesicular stomatitis virus (VSV) pseudotyped with SARS-CoV-2 G614 S (<xref ref-type="bibr" rid="R16">Kaname et al., 2010</xref>; <xref ref-type="bibr" rid="R21">Lempp et al., 2021</xref>). Delta breakthrough infections resulted in neutralizing GMTs of 2.7×10<sup>3</sup> after 30 days and 2.9×10<sup>3</sup> after 60 days (<xref ref-type="fig" rid="F2">Figure 2A</xref>, <xref ref-type="supplementary-material" rid="SD1">Figures S3-S4</xref>). We also observed potent neutralizing activity for infected/vaccinated subject sera with GMTs of 3.1×10<sup>3</sup>, 2.6×10<sup>3</sup> and 1.8×10<sup>3</sup> at 10 days, 112 days and 180 days post second vaccine dose, respectively, and increased 2.5 fold to 7.6×10<sup>3</sup> 10 days post third vaccine dose (<xref ref-type="fig" rid="F2">Figure 2A</xref>, <xref ref-type="supplementary-material" rid="SD1">Figures S5-S8</xref>). Vaccinated-only individuals had serum neutralizing activity of 3.7×10<sup>2</sup>, 1.4×10<sup>2</sup> and 1.3×10<sup>2</sup> at 10, 112 and 180 days post second vaccine dose which rose to 3.1×10<sup>3</sup> after a third vaccine dose (<xref ref-type="fig" rid="F2">Figure 2A</xref>, <xref ref-type="supplementary-material" rid="SD1">Figures S9-S12</xref>). This corresponds to an 8.2 fold increase when comparing 10 days after each dose, yielding a potency comparable to Delta breakthrough cases 30 days after infection and infected/vaccinated subjects 10 days post second vaccine dose. HCS had weak neutralizing potency (GMT 3.5×10<sup>1</sup>) (<xref ref-type="fig" rid="F2">Figure 2A</xref>, <xref ref-type="supplementary-material" rid="SD1">Figure S13</xref>). These data suggest that the number of exposures to S is more important than the type of exposure (infection vs. vaccination) to determine the magnitude of serum neutralizing activity. However, the approximately ten fold greater and constant neutralizing antibody GMTs measured over time for Delta breakthrough and infected/vaccinated cohorts set these 2 groups apart compared to vaccinated-only individuals (who experienced a neutralizing GMT decay of ~55% over 6 months after the second vaccine dose). These findings are in agreement with studies of individuals infected and subsequently vaccinated with mRNA vaccines or Jansen Ad26.COV2.S (<xref ref-type="bibr" rid="R17">Keeton et al., 2021</xref>; <xref ref-type="bibr" rid="R20">Krammer et al., 2021</xref>; <xref ref-type="bibr" rid="R37">Saadat et al., 2021</xref>; <xref ref-type="bibr" rid="R41">Stamatatos et al., 2021</xref>). Hence, multiple types of exposure or increased number of exposures to SARS-CoV-2 antigen(s) enhance the magnitude and durability of serum neutralizing activity possibly due to sustained antibody production by long lived plasma cells, increased affinity maturation yielding antibodies with greater neutralization potency, or a combination of both.</p>
<p id="P9">We also observed durable neutralizing activity for the Delta breakthrough serum samples against both Delta S and Beta S VSV pseudoviruses for which we determined GMTs of 1.9×10<sup>3</sup> (Delta S) and 8.8×10<sup>2</sup> (Beta S) after 30 days and 2.5×10<sup>3</sup> (Delta S) and 1.0×10<sup>3</sup> (Beta S) after 60 days (<xref ref-type="fig" rid="F2">Figure 2B-C</xref>). The dampening in neutralization potency relative to G614 S VSV for both Delta S (1.2-1.4 fold GMT reduction) and Beta S (2.9-3.0 fold GMT reduction) was smaller than previous findings with vaccinated-only or convalescent cohorts (<xref ref-type="bibr" rid="R6">Cele et al., 2021</xref>; <xref ref-type="bibr" rid="R25">Madhi et al., 2021</xref>; <xref ref-type="bibr" rid="R27">McCallum et al., 2021a</xref>; <xref ref-type="bibr" rid="R35">Planas et al., 2021</xref>; <xref ref-type="bibr" rid="R46">Walls et al., 2021a</xref>; <xref ref-type="bibr" rid="R51">Wibmer et al., 2021</xref>). For infected/vaccinated subjects, we determined GMTs of 1.6×10<sup>3</sup>, 1.4×10<sup>3</sup>, and 8.9×10<sup>2</sup> at 10, 112 and 180 days post second vaccine dose against Delta S VSV, respectively, corresponding to a 1.8-2.0 fold GMT reduction relative to G614 S VSV (<xref ref-type="fig" rid="F2">Figure 2A-B</xref>). After receiving a third vaccine dose, these individuals experienced a 2.0 fold increase in neutralizing titers against Delta S VSV (GMT 3.3×10<sup>3</sup>), corresponding to a 2.3 fold GMT reduction relative to G614 S VSV. Therefore, although the magnitude of neutralizing GMT increased, the breadth of broadly neutralizing antibody responses remains similar against Delta S VSV (<xref ref-type="fig" rid="F2">Figure 2A-B</xref>). Beta S VSV neutralizing GMTs were 9.9×10<sup>2</sup>, 7.9×10<sup>2</sup> and 4.8×10<sup>2</sup> at 10, 112 and 180 days post second vaccine dose, respectively, corresponding to a 3.1-3.8 GMT fold change compared to G614 S VSV (<xref ref-type="fig" rid="F2">Figure 2A,C</xref>). Following the third vaccination, these individuals experienced a 2.0 fold increase in neutralizing titers against Beta S VSV (GMT 1.9×10<sup>3</sup>), yielding a 3.9 fold GMT reduction relative to G614 S VSV. The vaccinated-only cohort had neutralizing GMTs against Delta S VSV of 7.5×10<sup>1</sup>, 8.2×10<sup>1</sup> and 7.4×10<sup>1</sup> at 10, 112 and 180 days post second vaccine dose, respectively, corresponding to a 1.7-5 fold GMT reduction relative to G614 S VSV (<xref ref-type="fig" rid="F2">Figure 2B</xref>). Triple vaccinated-only subjects had neutralizing antibody GMTs of 1.4×10<sup>3</sup>, an 18.8 fold increase compared to the same individuals after receiving only two vaccine doses at the same time point (<xref ref-type="fig" rid="F2">Figure 2B</xref>). Beta S VSV pseudovirus neutralizing GMTs were 7.3×10<sup>1</sup>, 3.6×10<sup>1</sup> and 2.8×10<sup>1</sup> at 10, 112 and 180 days post second vaccine dose, respectively (<xref ref-type="fig" rid="F2">Figure 2C</xref>). This corresponds to a 4.0-5.1 fold GMT reduction of serum neutralizing activity relative to G614 S VSV. Triple vaccinated-only subjects displayed a 9.0 fold neutralizing GMT increase (6.6×10<sup>2</sup>) compared to the same time point after receiving only two vaccine doses, consistent with enhanced resilience to this variant. These data suggest that repeated exposures, even to a distinct antigen, improves the potency and resilience of serum neutralizing activity to variants, including against Beta S VSV (<xref ref-type="bibr" rid="R47">Walls et al., 2021b</xref>) for which an average ~7 fold dampening of potency has been reported in the literature (mostly comprising infected-only and vaccinated-only subjects) (<ext-link ext-link-type="uri" xlink:href="https://covdb.stanford.edu/">https://covdb.stanford.edu/</ext-link>), in line with previous studies of infected/vaccinated individuals (<xref ref-type="bibr" rid="R17">Keeton et al., 2021</xref>; <xref ref-type="bibr" rid="R41">Stamatatos et al., 2021</xref>). Moreover, we observed a subtle advantage of mixed cohorts, including subjects who experienced both infections and vaccination (irrespective of the order) in terms of neutralization breadth against SARS-CoV-2 variants relative to triple vaccinated-only individuals. It remains to be determined if waning of binding and neutralizing GMTs will occur with similar kinetics after the third immunization of vaccinated-only subjects than after two doses or if they will mirror the durable antibody responses observed in Delta breakthrough and infected/vaccinated cohorts.</p>
<p id="P10">To assess the breadth of serum neutralizing activity among these different cohorts against viruses belonging to a different sarbecovirus clade than SARS-CoV-2, we used a SARS-CoV S VSV pseudotype. Delta breakthrough cases had neutralizing GMTs of 1.1×10<sup>2</sup>, and 7.9×10<sup>1</sup> at 30 and 60 days post positive PCR test (<xref ref-type="fig" rid="F2">Figure 2D</xref>) whereas the 2X infected/vaccinated cohort had GMTs of 1.1×10<sup>2</sup>, 5.6×10<sup>1</sup> and 4.4×10<sup>1</sup> at 10, 112 and 180 days post second vaccine dose, respectively (<xref ref-type="fig" rid="F2">Figure 2D</xref>). This corresponds to GMT reductions of 24-36-fold (Delta breakthrough) and 28-46 fold (infected/vaccinated) compared to G614 S VSV. After receiving a third vaccine dose, infected/vaccinated individuals had ~2.5 fold enhanced serum neutralizing responses against SARS-CoV S VSV (GMT of 2.8×10<sup>2</sup>) relative to the same subjects at 10 days post second vaccination. Although this amounts to a 26 fold reduction compared to peak neutralizing G614 S VSV GMT,, this is a similar neutralizing activity than that of vaccinated-only individuals against G614 after 2 doses (GMT 3.7×10<sup>2</sup>). The vaccinated-only cohort had neutralizing GMTs of 1.7×10<sup>1</sup>, 1.3×10<sup>1</sup> and 1.2×10<sup>1</sup> at 10, 112 and 180 days post second vaccine dose, respectively, which were boosted to 1.4×10<sup>2</sup> after the third vaccination (<xref ref-type="fig" rid="F2">Figure 2D</xref>). The latter GMT matches serum neutralizing activity of Delta breakthrough cases or of infected/vaccinated individuals (after two vaccinations),, further suggesting that the number of exposures is more important than the type of exposure. No SARS-CoV neutralization was detected for HCS, in line with the weak overall serum neutralizing activity of this cohort across any sarbecoviruses (<xref ref-type="fig" rid="F2">Figure 2D</xref>).</p>
<p id="P11">We show that Delta breakthrough cases or infected/vaccinated subjects are endowed with greater potency, breadth and durability of serum neutralizing activity relative to individuals who received 2 doses of COVID-19 vaccine or those who were only infected by SARS-CoV-2 in 2020. Serum neutralizing GMTs for the Delta breakthrough cases and infected/vaccinated subjects were greater against the Delta and Beta S variants at all time points than that of vaccinated-only individuals (after two doses) against G614 S pseudovirus at peak titers. The latter levels of neutralization potency were associated with ~95% protection from symptomatic COVID-19 disease in phase 3 clinical trials of the Pfizer Cominarty (<xref ref-type="bibr" rid="R36">Polack et al., 2020</xref>) and Moderna mRNA-1273 (<xref ref-type="bibr" rid="R2">Baden et al., 2021</xref>) vaccines and are reminiscent of observations made with infected/vaccinated samples (<xref ref-type="bibr" rid="R41">Stamatatos et al., 2021</xref>). The marked enhancement of serum neutralizing activity for vaccinated-only subjects after three doses, to levels comparable to Delta breakthrough and infected/vaccinated cases, suggest that the number of exposures to SARS-CoV-2 S, whether through vaccination or infection, correlates with the strength of neutralizing antibody responses as well as resilience to variants. It remains to be determined whether the number of exposures also correlates with durability of antibody responses for vaccinated-only individuals, as shown here with Delta breakthrough cases up to 60 days and infected/vaccinated subjects for 180 days. The reduction of serum neutralizing activity against SARS-CoV presented here following up to 3 SARS-CoV-2 S exposures, along with previous studies (<xref ref-type="bibr" rid="R26">Martinez et al., 2021</xref>; <xref ref-type="bibr" rid="R41">Stamatatos et al., 2021</xref>; <xref ref-type="bibr" rid="R46">Walls et al., 2021a</xref>), suggest that combinations of COVID-19 disease and vaccination would leave the population vulnerable to infection by a genetically divergent sarbecovirus, due to the more extensive sequence differences between SARS-CoV-2 S and SARS-CoV S compared to any two SARS-CoV-2 S variants. Four exposures to SARS-CoV-2 S, through infection followed by three vaccinations, elicit SARS-CoV serum neutralizing titers with a magnitude that is equivalent to protective levels for SARS-CoV-2 based on clinical trial evaluation of COVID-19 vaccines (<xref ref-type="bibr" rid="R2">Baden et al., 2021</xref>; <xref ref-type="bibr" rid="R36">Polack et al., 2020</xref>). These findings suggest that repeated exposures may improve elicitation of broadly neutralizing sarbecovirus antibodies, but not broadly reactive beta-coronavirus antibodies based on the comparable cross-reactive responses to OC43 and HKU1 S observed for all cohorts. Moreover, a recent study indicated that survivors of SARS-CoV infection who subsequently received a COVID-19 vaccine had broader sarbecovirus neutralizing antibody responses than subjects only exposed to SARS-CoV-2 virus or vaccine (<xref ref-type="bibr" rid="R44">Tan et al., 2021</xref>). These data lend further support to the ongoing development of several vaccine candidates (<xref ref-type="bibr" rid="R8">Cohen et al., 2021</xref>; <xref ref-type="bibr" rid="R26">Martinez et al., 2021</xref>; <xref ref-type="bibr" rid="R46">Walls et al., 2021a</xref>) designed to specifically elicit broad sarbecovirus immunity and could protect against SARS-CoV-2 variants as well as putative future zoonotic sarbecoviruses.</p>
<sec id="S1" sec-type="methods" specific-use="web-only">
<title>Methods</title>
<sec id="S2">
<title>Human Sera/Plasma</title>
<p id="P12">Blood samples were collected from participants as part of the Hospitalized or Ambulatory Adults with Respiratory Viral Infections (HAARVI) study and was approved by the University of Washington Human Subjects Division Institutional Review Board (STUDY00000959). Baseline socio-demographic and clinical data for these individuals are summarized in <xref ref-type="supplementary-material" rid="SD1">Tables S1-S5</xref>. All samples were sera except for the 60 day Delta breakthrough samples which were ACD plasma.</p>
</sec>
<sec id="S3">
<title>Sequencing of Delta Breakthrough Individuals</title>
<p id="P13">Participants were enrolled after SARS-CoV-2 positive RT-PCR results with S-Gene Dropout. SARS-CoV-2 genome sequencing was then conducted using a targeted enrichment approach to confirm Delta variant status. RNA from positive specimens was converted to cDNA using random hexamers and reverse transcriptase (Superscript IV, Thermo) and a sequencing library was constructed using the Illumina TruSeq RNA Library Prep for Enrichment kit (Illumina). The sequencing library was enriched for SARS-CoV-2 using the Twist Respiratory Virus Research Panel (Twist). Libraries were sequenced on a MiSeq or NextSeq instruments. The resulting reads were assembled against the SARS-CoV-2 reference genome Wuhan-Hu-1/2019 (Genbank accession MN908947) using the bioinformatics pipeline <ext-link ext-link-type="uri" xlink:href="https://github.com/seattleflu/assembly">https://github.com/seattleflu/assembly</ext-link>. Consensus sequences were deposited to Genbank and GISAID (<xref ref-type="bibr" rid="R3">Bedford et al., 2020</xref>). Sequence quality was determined using Nextclade version 1.0.0-alpha.8 (<ext-link ext-link-type="uri" xlink:href="https://clades.nextstrain.org/">https://clades.nextstrain.org/</ext-link>). Lineage was assigned using the Pangolin COVID-19 Lineage Assigner version 3.1.11 (<ext-link ext-link-type="uri" xlink:href="https://pangolin.cog-uk.io/">https://pangolin.cog-uk.io/</ext-link>)(<xref ref-type="bibr" rid="R33">Paredes et al., 2021</xref>).</p>
</sec>
<sec id="S4">
<title>Recombinant Protein Expression and purification</title>
<p id="P14">The SARS-CoV-2 Hexapro S (<xref ref-type="bibr" rid="R14">Hsieh et al., 2020</xref>), SARS-CoV-2 Delta VFLIP S with the native furin cleavage site (<xref ref-type="bibr" rid="R27">McCallum et al., 2021a</xref>; <xref ref-type="bibr" rid="R31">Olmedillas et al., 2021</xref>), SARS-CoV S 2P (<xref ref-type="bibr" rid="R32">Pallesen et al., 2017</xref>; <xref ref-type="bibr" rid="R47">Walls et al., 2020b</xref>), HKU1 S2P, and OC43 S(<xref ref-type="bibr" rid="R45">Tortorici et al., 2019</xref>) ectodomains were produced in Expi293F Cells (ThermoFisher Scientific) grown in suspension using Expi293 Expression Medium (ThermoFisher Scientific) at 37°C in a humidified 8% CO2 incubator with constant rotation at 130 rpm. Cells grown to a density of 3 million cells per mL were transfected using the ExpiFectamine 293 Transfection Kit (ThermoFisher Scientific) and cultivated for four days at which point the supernatant was harvested. SARS-CoV-2 Hexapro S, SARS-CoV-2 Delta VFLIP S, SARS-CoV S2P, and HKU1 S2P ectodomains were purified from clarified supernatants using a HisTrapHP column (Cytiva) and washed with 10 column volumes of 25 mM sodium phosphate pH 8.0 and 150 mM NaCl before elution on a gradient up to 500 mM imidazole. OC43 S fused to strep tag, the supernatant was clarified by 10 minute centrifugation at 800xg and brought to 100 mM Tris-HCL pH 8, 150 mM NaCl, and 18.1 mL/liter biotin blocking solution (BioLock). After a 20-minute incubation, supernatant was further centrifuged at 10,000xg for 20 minutes. Supernatant was then bound to a 1 mL StrepTrap HP column (Cytiva) and washed with 10 column volumes of 100 mM Tris-HCl, 150 mM NaCl, and 1 mM EDTA pH 8 before elution in wash buffer supplemented with 2.5 mM desthiobiotin. Purified protein was buffer exchanged into 20 mM Tris-HCl pH 8.0 and 100 mM NaCl, concentrated using 100 kDa MWCO centrifugal filters (Amicon Ultra) to 1-2 mg/mL, and flash frozen.</p>
</sec>
<sec id="S5">
<title>ELISA</title>
<p id="P15">For anti-S ELISA, 50 μL of 2-6 μg/mL S was plated onto 384-well Nunc Maxisorp (ThermoFisher) plates in PBS and sealed overnight at 4°C. The next day plates were washed 4 × in Tris Buffered Saline Tween (TBST-20mM Tris pH 8, 150mM NaCl, 0.1% Tween) using a plate washer (BioTek) and blocked with Casein (ThermoFisher) for 1 h at 37°C. Plates were washed 4 × in TBST and 1:5 serial dilutions of human sera or plasma were made in 50 μL TBST starting at 1:10, 1:50, or 1:250 and incubated at 37°C for 1 h. Plates were washed 4 × in TBST, then anti-human (Invitrogen) horseradish peroxidase-conjugated antibodies were diluted 1:5,000 and 50 μL added to each well and incubated at 37°C for 1 h. Plates were washed 4 × in TBST and 50 μL of TMB (SeraCare) was added to every well for 5 min at room temperature. The reaction was quenched with the addition of 50 μL of 1 N HCl. Plates were immediately read at 450 nm on a VarioSkanLux plate reader (ThermoFisher) and data plotted and fit in Prism (GraphPad) using nonlinear regression sigmoidal, 4PL, X is log(concentration) to determine EC<sub>50</sub> values from curve fits. Where the curve did not reach an OD450 of 4, a constraint of OD450 4 was placed on the upper bounds of the fit.</p>
</sec>
<sec id="S6">
<title>VSV Pseudovirus Production</title>
<p id="P16">G614 SARS-CoV-2 S (YP 009724390.1), Delta S, Beta S, and SARS-CoV S pseudotyped VSV viruses were prepared as described previously (<xref ref-type="bibr" rid="R27">McCallum et al., 2021a</xref>; <xref ref-type="bibr" rid="R47">Walls et al., 2021b</xref>). Briefly, HEK293T cells in DMEM supplemented with 10% FBS, 1% PenStrep seeded in 10-cm dishes were transfected with the plasmid encoding for the corresponding S glycoprotein using lipofectamine 2000 (Life Technologies) following the manufacturer’s instructions. One day posttransfection, cells were infected with VSV(G*ΔG-luciferase)(<xref ref-type="bibr" rid="R16">Kaname et al., 2010</xref>) and after 2 h were washed five times with DMEM before adding medium supplemented with anti-VSV-G antibody (I1-mouse hybridoma supernatant, CRL-2700, ATCC). Virus pseudotypes were harvested 18-24 h post-inoculation, clarified by centrifugation at 2,500 x g for 5 min, filtered through a 0.45 μm cut off membrane, concentrated 10 times with a 30 kDa cut off membrane, aliquoted and stored at -80°C.</p>
</sec>
<sec id="S7">
<title>VSV Pseudovirus Neutralization</title>
<p id="P17">VeroE6-TMPRSS2 (<xref ref-type="bibr" rid="R21">Lempp et al., 2021</xref>) were cultured in DMEM with 10% FBS (Hyclone), 1% PenStrep and 8 μg/mL puromycin (to ensure retention of TMPRSS2) with 5% CO<sub>2</sub> in a 37°C incubator (ThermoFisher). Cells were trypsinized using 0.05% trypsin and plated to 40,000 cells/well. The following day, cells were checked to be at 80% confluence. In an empty half-area 96-well plate, a 1:3 serial dilution of sera was made in DMEM and diluted pseudovirus was then added and incubated at room temperature for 30-60 min before addition of the sera-virus mixture to the cells at 37°C. 2 hours later, 40 μL of a DMEM solution containing 20% FBS and 2% PenStrep was added to each well. After 17-20 hours, 40 μL/well of One-Glo-EX substrate (Promega) was added to the cells and incubated in the dark for 5-10 min prior to reading on a BioTek plate reader. Measurements were done at least in duplicate using distinct batches of pseudoviruses and one representative experiment is shown. Relative luciferase units were plotted and normalized in Prism (GraphPad). Nonlinear regression of log(inhibitor) versus normalized response was used to determine IC<sub>50</sub> values from curve fits. Normality was tested using the D’agostino-Pearson test and in the absence of a normal distribution, kruskal-wallis tests were used to compare two groups to determine whether differences reached statistical significance. Fold changes were determined by comparing individual animal IC50 and then averaging the individual fold changes for reporting.</p>
</sec>
</sec>
<sec sec-type="supplementary-material" id="SM">
<title>Supplementary Material</title>
<supplementary-material content-type="local-data" id="SD1">
<label>Supplementary Material</label>
<media xlink:href="EMS141105-supplement-Supplementary_Material.pdf" mimetype="application" mime-subtype="pdf" id="N66707" position="anchor"/>
</supplementary-material>
</sec>
</body>
<back>
<ack id="S8">
<title>Acknowledgements</title>
<p>We thank Hideki Tani (University of Toyama) for providing the reagents necessary for preparing VSV pseudotyped viruses. We thank Antonio Lanzavecchia for coordination of the SARS-CoV-2 naive blood donors.</p>
<sec id="S9">
<title>Funding</title>
<p>This study was supported by the National Institute of Allergy and Infectious Diseases (DP1AI158186 and HHSN272201700059C to D.V.), a Pew Biomedical Scholars Award (D.V.), an Investigators in the Pathogenesis of Infectious Disease Awards from the Burroughs Wellcome Fund (D.V.), Fast Grants (D.V.) and the Bill and Melinda Gates Foundation (OPP1156262 to D.V.). D.V. is an Investigator of the Howard Hughes Medical Institute..</p>
</sec>
</ack>
<sec sec-type="data-availability" id="S10">
<title>Data and materials availability</title>
<p id="P18">Materials generated in this study will be made available on request after signing a materials transfer agreement with the University of Washington. This work is licensed under a Creative CommonsAttribution 4.0 International (CC BY 4.0) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>. This license does not apply tofigures/photos/artwork or other content included in the article that is credited to a third party;obtain authorization from the rights holder before using such material.</p>
</sec>
<fn-group>
<fn id="FN1" fn-type="con">
<p id="P19">
<bold>Author contributions:</bold> A.C.W., J.E.B., and D.V. conceived the project. A.C.W. and D.V. designed the experiments and supervised this study. K.R.S., M.J.N., A.J., and C.S. carried out ELISAs. A.C.W, K.R.S, and M.J.N produced pseudovirus and ran pseudovirus neutralization assays. J.E.B., A.J., and M.M. expressed and purified proteins. E.A.G., E.J.D.A., and A.G. coordinated and ran Roche Anti N experiments. E.N.F., J.L., A.L., and H.C. coordinated collection of and provided clinical samples. A.C.W., K.R.S, M.J.N., A.J., C.S., J.E.B., and D.V. analyzed the data. A.C.W. and D.V. wrote the manuscript with input from all authors.</p>
</fn>
<fn id="FN2" fn-type="conflict">
<p id="P20">
<bold>Competing interests:</bold> The Veesler laboratory has received an unrelated sponsored research agreement from Vir Biotechnology Inc. A.C.W and D.V. are named as inventors on patent applications filed by the University of Washington for SARS-CoV-2 and sarbecovirus receptor binding domain nanoparticle vaccines. H.Y.C. is a consultant for Merck, Pfizer, Ellume, and the Bill and Melinda Gates Foundation and has received support from Cepheid and Sanofi-Pasteur. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</fn>
</fn-group>
<ref-list>
<ref id="R1">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arunachalam</surname>
<given-names>PS</given-names>
</name>
<name>
<surname>Walls</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Golden</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Atyeo</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Fischinger</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Aye</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Navarro</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Lai</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Edara</surname>
<given-names>VV</given-names>
</name>
<etal/>
</person-group>
<article-title>Adjuvanting a subunit COVID-19 vaccine to induce protective immunity</article-title>
<source>Nature</source>
<year>2021</year>
</element-citation>
</ref>
<ref id="R2">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baden</surname>
<given-names>LR</given-names>
</name>
<name>
<surname>El Sahly</surname>
<given-names>HM</given-names>
</name>
<name>
<surname>Essink</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Kotloff</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Frey</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Novak</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Diemert</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Spector</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Rouphael</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Creech</surname>
<given-names>CB</given-names>
</name>
<etal/>
</person-group>
<article-title>Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine</article-title>
<source>N Engl J Med</source>
<year>2021</year>
<volume>384</volume>
<fpage>403</fpage>
<lpage>416</lpage>
</element-citation>
</ref>
<ref id="R3">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bedford</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Greninger</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Roychoudhury</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Starita</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Famulare</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>M-L</given-names>
</name>
<name>
<surname>Nalla</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Pepper</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Reinhardt</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>H</given-names>
</name>
<etal/>
</person-group>
<article-title>Cryptic transmission of SARS-CoV-2 in Washington state</article-title>
<source>Science</source>
<year>2020</year>
<volume>370</volume>
<fpage>571</fpage>
<lpage>575</lpage>
</element-citation>
</ref>
<ref id="R4">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Case</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Rothlauf</surname>
<given-names>PW</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Kafai</surname>
<given-names>NM</given-names>
</name>
<name>
<surname>Fox</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>BK</given-names>
</name>
<name>
<surname>Shrihari</surname>
<given-names>S</given-names>
</name>
<name>
<surname>McCune</surname>
<given-names>BT</given-names>
</name>
<name>
<surname>Harvey</surname>
<given-names>IB</given-names>
</name>
<name>
<surname>Keeler</surname>
<given-names>SP</given-names>
</name>
<etal/>
</person-group>
<article-title>Replication-Competent Vesicular Stomatitis Virus Vaccine Vector Protects against SARS-CoV-2-Mediated Pathogenesis in Mice</article-title>
<source>Cell Host Microbe</source>
<year>2020a</year>
<volume>28</volume>
<fpage>465</fpage>
<lpage>474</lpage>
<elocation-id>e4</elocation-id>
</element-citation>
</ref>
<ref id="R5">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Case</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Rothlauf</surname>
<given-names>PW</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Bloyet</surname>
<given-names>L-M</given-names>
</name>
<name>
<surname>Zeng</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Tahan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Droit</surname>
<given-names>L</given-names>
</name>
<etal/>
</person-group>
<article-title>Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2</article-title>
<source>Cell Host Microbe</source>
<year>2020b</year>
<volume>28</volume>
<fpage>475</fpage>
<lpage>485</lpage>
<elocation-id>e5</elocation-id>
</element-citation>
</ref>
<ref id="R6">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cele</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gazy</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Jackson</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Hwa</surname>
<given-names>S-H</given-names>
</name>
<name>
<surname>Tegally</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Lustig</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Giandhari</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Pillay</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Wilkinson</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Naidoo</surname>
<given-names>Y</given-names>
</name>
<etal/>
</person-group>
<article-title>Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma</article-title>
<source>Nature</source>
<year>2021</year>
<volume>593</volume>
<fpage>142</fpage>
<lpage>146</lpage>
</element-citation>
</ref>
<ref id="R7">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cho</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Muecksch</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Schaefer-Babajew</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Finkin</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gaebler</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Ramos</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Cipolla</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mendoza</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Agudelo</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>
<article-title>Anti-SARS-CoV-2 receptor binding domain antibody evolution after mRNA vaccination</article-title>
<source>Nature</source>
<year>2021</year>
</element-citation>
</ref>
<ref id="R8">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cohen</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Gnanapragasam</surname>
<given-names>PNP</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>YE</given-names>
</name>
<name>
<surname>Hoffman</surname>
<given-names>PR</given-names>
</name>
<name>
<surname>Ou</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kakutani</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Keeffe</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>H-J</given-names>
</name>
<name>
<surname>Howarth</surname>
<given-names>M</given-names>
</name>
<name>
<surname>West</surname>
<given-names>AP</given-names>
</name>
<etal/>
</person-group>
<article-title>Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice</article-title>
<source>Science</source>
<year>2021</year>
<volume>371</volume>
<fpage>735</fpage>
<lpage>741</lpage>
</element-citation>
</ref>
<ref id="R9">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Collier</surname>
<given-names>A-RY</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Mcmahan</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Jacob-Dolan</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Chandrashekar</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Tierney</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Ansel</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Rowe</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>
<article-title>Immune Responses in Fully Vaccinated Individuals Following Breakthrough Infection with the SARS-CoV-2 Delta Variant in Provincetown, Massachusetts</article-title>
<source>medRxiv</source>
<year>2021</year>
</element-citation>
</ref>
<ref id="R10">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Corbett</surname>
<given-names>KS</given-names>
</name>
<name>
<surname>Nason</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Flach</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Gagne</surname>
<given-names>M</given-names>
</name>
<name>
<surname>O’Connell</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Johnston</surname>
<given-names>TS</given-names>
</name>
<name>
<surname>Shah</surname>
<given-names>SN</given-names>
</name>
<name>
<surname>Edara</surname>
<given-names>VV</given-names>
</name>
<name>
<surname>Floyd</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Lai</surname>
<given-names>L</given-names>
</name>
<etal/>
</person-group>
<article-title>Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates</article-title>
<source>Science</source>
<year>2021</year>
</element-citation>
</ref>
<ref id="R11">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Corti</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Purcell</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Snell</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Veesler</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Tackling COVID-19 with neutralizing monoclonal antibodies</article-title>
<source>Cell</source>
<year>2021</year>
</element-citation>
</ref>
<ref id="R12">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Falsey</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Frenck</surname>
<given-names>RW</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Walsh</surname>
<given-names>EE</given-names>
</name>
<name>
<surname>Kitchin</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Absalon</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gurtman</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lockhart</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bailey</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Swanson</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>X</given-names>
</name>
<etal/>
</person-group>
<article-title>SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3</article-title>
<source>N Engl J Med</source>
<year>2021</year>
<volume>385</volume>
<fpage>1627</fpage>
<lpage>1629</lpage>
</element-citation>
</ref>
<ref id="R13">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hassan</surname>
<given-names>AO</given-names>
</name>
<name>
<surname>Feldmann</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Curiel</surname>
<given-names>DT</given-names>
</name>
<name>
<surname>Okumura</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Tang-Huau</surname>
<given-names>T-L</given-names>
</name>
<name>
<surname>Case</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Meade-White</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Callison</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>RE</given-names>
</name>
<etal/>
</person-group>
<article-title>A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques</article-title>
<source>Cell Rep Med</source>
<year>2021</year>
<volume>2</volume>
<elocation-id>100230</elocation-id>
</element-citation>
</ref>
<ref id="R14">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hsieh</surname>
<given-names>C-L</given-names>
</name>
<name>
<surname>Goldsmith</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Schaub</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>DiVenere</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Kuo</surname>
<given-names>H-C</given-names>
</name>
<name>
<surname>Javanmardi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Le</surname>
<given-names>KC</given-names>
</name>
<name>
<surname>Wrapp</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>AG</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y</given-names>
</name>
<etal/>
</person-group>
<article-title>Structure-based design of prefusion-stabilized SARS-CoV-2 spikes</article-title>
<source>Science</source>
<year>2020</year>
<volume>369</volume>
<fpage>1501</fpage>
<lpage>1505</lpage>
</element-citation>
</ref>
<ref id="R15">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Johnson</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Bailey</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Kalveram</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Lokugamage</surname>
<given-names>KG</given-names>
</name>
<name>
<surname>Muruato</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Zou</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Juelich</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>JK</given-names>
</name>
<etal/>
</person-group>
<article-title>Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis</article-title>
<source>Nature</source>
<year>2021</year>
<volume>591</volume>
<fpage>293</fpage>
<lpage>299</lpage>
</element-citation>
</ref>
<ref id="R16">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kaname</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Tani</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kataoka</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Shiokawa</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Taguwa</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Abe</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Moriishi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kinoshita</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Matsuura</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>Acquisition of complement resistance through incorporation of CD55/decay-accelerating factor into viral particles bearing baculovirus GP64</article-title>
<source>J Virol</source>
<year>2010</year>
<volume>84</volume>
<fpage>3210</fpage>
<lpage>3219</lpage>
</element-citation>
</ref>
<ref id="R17">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Keeton</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Richardson</surname>
<given-names>SI</given-names>
</name>
<name>
<surname>Moyo-Gwete</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Hermanus</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Tincho</surname>
<given-names>MB</given-names>
</name>
<name>
<surname>Benede</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Manamela</surname>
<given-names>NP</given-names>
</name>
<name>
<surname>Baguma</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Makhado</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Ngomti</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>
<article-title>Prior infection with SARS-CoV-2 boosts and broadens Ad26.COV2.S immunogenicity in a variant-dependent manner</article-title>
<source>Cell Host Microbe</source>
<year>2021</year>
<volume>29</volume>
<fpage>1611</fpage>
<lpage>1619</lpage>
<elocation-id>e5</elocation-id>
</element-citation>
</ref>
<ref id="R18">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khoury</surname>
<given-names>DS</given-names>
</name>
<name>
<surname>Cromer</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Reynaldi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Schlub</surname>
<given-names>TE</given-names>
</name>
<name>
<surname>Wheatley</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Juno</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Subbarao</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kent</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Triccas</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Davenport</surname>
<given-names>MP</given-names>
</name>
</person-group>
<article-title>Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection</article-title>
<source>Nat Med</source>
<year>2021</year>
<volume>27</volume>
<fpage>1205</fpage>
<lpage>1211</lpage>
</element-citation>
</ref>
<ref id="R19">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kirchdoerfer</surname>
<given-names>RN</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Pallesen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wrapp</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Turner</surname>
<given-names>HL</given-names>
</name>
<name>
<surname>Cottrell</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Corbett</surname>
<given-names>KS</given-names>
</name>
<name>
<surname>Graham</surname>
<given-names>BS</given-names>
</name>
<name>
<surname>McLellan</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Ward</surname>
<given-names>AB</given-names>
</name>
</person-group>
<article-title>Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis</article-title>
<source>Sci Rep</source>
<year>2018</year>
<volume>8</volume>
<elocation-id>15701</elocation-id>
</element-citation>
</ref>
<ref id="R20">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krammer</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Srivastava</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Alshammary</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Amoako</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Awawda</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Beach</surname>
<given-names>KF</given-names>
</name>
<name>
<surname>Bermúdez-González</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Bielak</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Carreño</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Chernet</surname>
<given-names>RL</given-names>
</name>
<etal/>
</person-group>
<article-title>Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine</article-title>
<source>N Engl J Med</source>
<year>2021</year>
<volume>384</volume>
<fpage>1372</fpage>
<lpage>1374</lpage>
</element-citation>
</ref>
<ref id="R21">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lempp</surname>
<given-names>FA</given-names>
</name>
<name>
<surname>Soriaga</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Montiel-Ruiz</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Benigni</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Noack</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>Y-J</given-names>
</name>
<name>
<surname>Bianchi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Walls</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Bowen</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>
<article-title>Lectins enhance SARS-CoV-2 infection and influence neutralizing antibodies</article-title>
<source>Nature</source>
<year>2021</year>
</element-citation>
</ref>
<ref id="R22">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Levine-Tiefenbrun</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Yelin</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Alapi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Katz</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Herzel</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Kuint</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Chodick</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Gazit</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Patalon</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kishony</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Viral loads of Delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2</article-title>
<source>Nat Med</source>
<year>2021</year>
</element-citation>
</ref>
<ref id="R23">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Deng</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Xiong</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Zou</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H</given-names>
</name>
<etal/>
</person-group>
<article-title>Viral infection and transmission in a large, well-traced outbreak caused by the SARS-CoV-2 Delta variant</article-title>
<source>medRxiv</source>
<year>2021</year>
</element-citation>
</ref>
<ref id="R24">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Xia</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ku</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Schindewolf</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Widen</surname>
<given-names>SG</given-names>
</name>
<name>
<surname>An</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Weaver</surname>
<given-names>SC</given-names>
</name>
<name>
<surname>Menachery</surname>
<given-names>VD</given-names>
</name>
<etal/>
</person-group>
<article-title>Delta spike P681R mutation enhances SARS-CoV-2 fitness over Alpha variant</article-title>
<source>bioRxiv</source>
<year>2021</year>
</element-citation>
</ref>
<ref id="R25">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Madhi</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Baillie</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Cutland</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Voysey</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Koen</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Fairlie</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Padayachee</surname>
<given-names>SD</given-names>
</name>
<name>
<surname>Dheda</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Barnabas</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Bhorat</surname>
<given-names>QE</given-names>
</name>
<etal/>
</person-group>
<article-title>Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant</article-title>
<source>N Engl J Med</source>
<year>2021</year>
<volume>384</volume>
<fpage>1885</fpage>
<lpage>1898</lpage>
</element-citation>
</ref>
<ref id="R26">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martinez</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Schäfer</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Leist</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>De la Cruz</surname>
<given-names>G</given-names>
</name>
<name>
<surname>West</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Atochina-Vasserman</surname>
<given-names>EN</given-names>
</name>
<name>
<surname>Lindesmith</surname>
<given-names>LC</given-names>
</name>
<name>
<surname>Pardi</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Parks</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Barr</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>
<article-title>Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice</article-title>
<source>Science</source>
<year>2021</year>
</element-citation>
</ref>
<ref id="R27">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McCallum</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Walls</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Sprouse</surname>
<given-names>KR</given-names>
</name>
<name>
<surname>Bowen</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Rosen</surname>
<given-names>LE</given-names>
</name>
<name>
<surname>Dang</surname>
<given-names>HV</given-names>
</name>
<name>
<surname>De Marco</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Franko</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Tilles</surname>
<given-names>SW</given-names>
</name>
<name>
<surname>Logue</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>
<article-title>Molecular basis of immune evasion by the Delta and Kappa SARS-CoV-2 variants</article-title>
<source>Science</source>
<year>2021a</year>
<elocation-id>eab18506</elocation-id>
</element-citation>
</ref>
<ref id="R28">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McCallum</surname>
<given-names>M</given-names>
</name>
<name>
<surname>De Marco</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lempp</surname>
<given-names>FA</given-names>
</name>
<name>
<surname>Tortorici</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Pinto</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Walls</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Beltramello</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Zatta</surname>
<given-names>F</given-names>
</name>
<etal/>
</person-group>
<article-title>N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2</article-title>
<source>Cell</source>
<year>2021b</year>
</element-citation>
</ref>
<ref id="R29">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McMahan</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Mercado</surname>
<given-names>NB</given-names>
</name>
<name>
<surname>Loos</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Tostanoski</surname>
<given-names>LH</given-names>
</name>
<name>
<surname>Chandrashekar</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Peter</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Atyeo</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>
<article-title>Correlates of protection against SARS-CoV-2 in rhesus macaques</article-title>
<source>Nature</source>
<year>2021</year>
<volume>590</volume>
<fpage>630</fpage>
<lpage>634</lpage>
</element-citation>
</ref>
<ref id="R30">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mlcochova</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Kemp</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Dhar</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Papa</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Meng</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Ferreira</surname>
<given-names>IATM</given-names>
</name>
<name>
<surname>Datir</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Collier</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Albecka</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>
<article-title>SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion</article-title>
<source>Nature</source>
<year>2021</year>
</element-citation>
</ref>
<ref id="R31">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Olmedillas</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Mann</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>YT</given-names>
</name>
<name>
<surname>Avalos</surname>
<given-names>RD</given-names>
</name>
</person-group>
<article-title>Structure-based design of a highly stable, covalently-linked SARS-CoV-2 spike trimer with improved structural properties and immunogenicity</article-title>
<source>bioRxiv</source>
<year>2021</year>
</element-citation>
</ref>
<ref id="R32">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pallesen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Corbett</surname>
<given-names>KS</given-names>
</name>
<name>
<surname>Wrapp</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Kirchdoerfer</surname>
<given-names>RN</given-names>
</name>
<name>
<surname>Turner</surname>
<given-names>HL</given-names>
</name>
<name>
<surname>Cottrell</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Becker</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>W</given-names>
</name>
<etal/>
</person-group>
<article-title>Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen</article-title>
<source>Proc Natl Acad Sci U S A</source>
<year>2017</year>
<volume>114</volume>
<fpage>E7348</fpage>
<lpage>E7357</lpage>
</element-citation>
</ref>
<ref id="R33">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Paredes</surname>
<given-names>MI</given-names>
</name>
<name>
<surname>Lunn</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Famulare</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Frisbie</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Painter</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Burstein</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Roychoudhury</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Mohamed Bakhash</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Perez</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group>
<article-title>Associations between SARS-CoV-2 variants and risk of COVID-19 hospitalization among confirmed cases in Washington State: a retrospective cohort study</article-title>
<source>medRxiv</source>
<year>2021</year>
</element-citation>
</ref>
<ref id="R34">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pinto</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Sauer</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Czudnochowski</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Low</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Tortorici</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Housley</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Noack</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Walls</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Bowen</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Guarino</surname>
<given-names>B</given-names>
</name>
<etal/>
</person-group>
<article-title>Broad betacoronavirus neutralization by a stem helix-specific human antibody</article-title>
<source>Science</source>
<year>2021</year>
<volume>373</volume>
<fpage>1109</fpage>
<lpage>1116</lpage>
</element-citation>
</ref>
<ref id="R35">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Planas</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Bruel</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Grzelak</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Guivel-Benhassine</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Staropoli</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Porrot</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Planchais</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Buchrieser</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Rajah</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Bishop</surname>
<given-names>E</given-names>
</name>
<etal/>
</person-group>
<article-title>Sensitivity of infectious SARS-CoV-2 B. 1.1.7 and B.1.351 variants to neutralizing antibodies</article-title>
<source>Nat Med</source>
<year>2021</year>
</element-citation>
</ref>
<ref id="R36">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Polack</surname>
<given-names>FP</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Kitchin</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Absalon</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gurtman</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lockhart</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Perez</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Pérez Marc</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Moreira</surname>
<given-names>ED</given-names>
</name>
<name>
<surname>Zerbini</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group>
<article-title>Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine</article-title>
<source>N Engl J Med</source>
<year>2020</year>
<volume>383</volume>
<fpage>2603</fpage>
<lpage>2615</lpage>
</element-citation>
</ref>
<ref id="R37">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saadat</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Rikhtegaran Tehrani</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Logue</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Newman</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Frieman</surname>
<given-names>MB</given-names>
</name>
<name>
<surname>Harris</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>Sajadi</surname>
<given-names>MM</given-names>
</name>
</person-group>
<article-title>Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2</article-title>
<source>JAMA</source>
<year>2021</year>
<volume>325</volume>
<fpage>1467</fpage>
<lpage>1469</lpage>
</element-citation>
</ref>
<ref id="R38">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saito</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Irie</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Suzuki</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Maemura</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Nasser</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Uriu</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kosugi</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Shirakawa</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Sadamasu</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kimura</surname>
<given-names>I</given-names>
</name>
<etal/>
</person-group>
<article-title>Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation</article-title>
<source>Nature</source>
<year>2021</year>
</element-citation>
</ref>
<ref id="R39">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sauer</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Tortorici</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>Y-J</given-names>
</name>
<name>
<surname>Walls</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Homad</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Acton</surname>
<given-names>OJ</given-names>
</name>
<name>
<surname>Bowen</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Xiong</surname>
<given-names>X</given-names>
</name>
<name>
<surname>de van der Schueren</surname>
<given-names>W</given-names>
</name>
<etal/>
</person-group>
<article-title>Structural basis for broad coronavirus neutralization</article-title>
<source>Nat Struct Mol Biol</source>
<year>2021</year>
<volume>28</volume>
<fpage>478</fpage>
<lpage>486</lpage>
</element-citation>
</ref>
<ref id="R40">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Song</surname>
<given-names>G</given-names>
</name>
<name>
<surname>He</surname>
<given-names>W-T</given-names>
</name>
<name>
<surname>Callaghan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Anzanello</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Ricketts</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Torres</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Beutler</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Vargas</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>
<article-title>Cross-reactive serum and memory B-cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection</article-title>
<source>Nat Commun</source>
<year>2021</year>
<volume>12</volume>
<fpage>2938</fpage>
</element-citation>
</ref>
<ref id="R41">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stamatatos</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Czartoski</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wan</surname>
<given-names>Y-H</given-names>
</name>
<name>
<surname>Homad</surname>
<given-names>LJ</given-names>
</name>
<name>
<surname>Rubin</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Glantz</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Neradilek</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Seydoux</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Jennewein</surname>
<given-names>MF</given-names>
</name>
<name>
<surname>MacCamy</surname>
<given-names>AJ</given-names>
</name>
<etal/>
</person-group>
<article-title>mRNA vaccination boosts crossvariant neutralizing antibodies elicited by SARS-CoV-2 infection</article-title>
<source>Science</source>
<year>2021</year>
</element-citation>
</ref>
<ref id="R42">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Suryadevara</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Shrihari</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gilchuk</surname>
<given-names>P</given-names>
</name>
<name>
<surname>VanBlargan</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Binshtein</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Zost</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Nargi</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Sutton</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Winkler</surname>
<given-names>ES</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>EC</given-names>
</name>
<etal/>
</person-group>
<article-title>Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein</article-title>
<source>Cell</source>
<year>2021</year>
<volume>184</volume>
<fpage>2316</fpage>
<lpage>2331</lpage>
<elocation-id>e15</elocation-id>
</element-citation>
</ref>
<ref id="R43">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Syed</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Taha</surname>
<given-names>TY</given-names>
</name>
<name>
<surname>Tabata</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>IP</given-names>
</name>
<name>
<surname>Ciling</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Khalid</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Sreekumar</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>P-Y</given-names>
</name>
<name>
<surname>Hayashi</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Soczek</surname>
<given-names>KM</given-names>
</name>
<etal/>
</person-group>
<article-title>Rapid assessment of SARS-CoV-2 evolved variants using virus-like particles</article-title>
<source>Science</source>
<year>2021</year>
<elocation-id>eabl6184</elocation-id>
</element-citation>
</ref>
<ref id="R44">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tan</surname>
<given-names>C-W</given-names>
</name>
<name>
<surname>Chia</surname>
<given-names>W-N</given-names>
</name>
<name>
<surname>Young</surname>
<given-names>BE</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Lim</surname>
<given-names>B-L</given-names>
</name>
<name>
<surname>Sia</surname>
<given-names>W-R</given-names>
</name>
<name>
<surname>Thein</surname>
<given-names>T-L</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>MI-C</given-names>
</name>
<name>
<surname>Leo</surname>
<given-names>Y-S</given-names>
</name>
<name>
<surname>Lye</surname>
<given-names>DC</given-names>
</name>
<etal/>
</person-group>
<article-title>Pan-Sarbecovirus Neutralizing Antibodies in BNT162b2-Immunized SARS-CoV-1 Survivors</article-title>
<source>N Engl J Med</source>
<year>2021</year>
<volume>385</volume>
<fpage>1401</fpage>
<lpage>1406</lpage>
</element-citation>
</ref>
<ref id="R45">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tortorici</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Walls</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Lang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Koerhuis</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Boons</surname>
<given-names>G-J</given-names>
</name>
<name>
<surname>Bosch</surname>
<given-names>B-J</given-names>
</name>
<name>
<surname>Rey</surname>
<given-names>FA</given-names>
</name>
<name>
<surname>de Groot</surname>
<given-names>RJ</given-names>
</name>
<etal/>
</person-group>
<article-title>Structural basis for human coronavirus attachment to sialic acid receptors</article-title>
<source>Nat Struct Mol Biol</source>
<year>2019</year>
<volume>26</volume>
<fpage>481</fpage>
<lpage>489</lpage>
</element-citation>
</ref>
<ref id="R46">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Walls</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>YJ</given-names>
</name>
<name>
<surname>Tortorici</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Wall</surname>
<given-names>A</given-names>
</name>
<name>
<surname>McGuire</surname>
<given-names>AT</given-names>
</name>
<name>
<surname>Veesler</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein</article-title>
<source>Cell</source>
<year>2020a</year>
<volume>181</volume>
<fpage>281</fpage>
<lpage>292</lpage>
<elocation-id>e6</elocation-id>
</element-citation>
</ref>
<ref id="R47">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Walls</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Xiong</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>Y-J</given-names>
</name>
<name>
<surname>Tortorici</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Snijder</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Quispe</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Cameroni</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Gopal</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Dai</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lanzavecchia</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>
<article-title>Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion</article-title>
<source>Cell</source>
<year>2020b</year>
<volume>183</volume>
<fpage>1732</fpage>
</element-citation>
</ref>
<ref id="R48">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Walls</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Miranda</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Schäfer</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Pham</surname>
<given-names>MN</given-names>
</name>
<name>
<surname>Greaney</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Arunachalam</surname>
<given-names>PS</given-names>
</name>
<name>
<surname>Navarro</surname>
<given-names>M-J</given-names>
</name>
<name>
<surname>Tortorici</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Rogers</surname>
<given-names>K</given-names>
</name>
<name>
<surname>O’Connor</surname>
<given-names>MA</given-names>
</name>
<etal/>
</person-group>
<article-title>Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines</article-title>
<source>Cell</source>
<year>2021a</year>
<volume>184</volume>
<fpage>5432</fpage>
<lpage>5447</lpage>
<elocation-id>e16</elocation-id>
</element-citation>
</ref>
<ref id="R49">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Walls</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Miranda</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Pham</surname>
<given-names>MN</given-names>
</name>
<name>
<surname>Schäfer</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Greaney</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Arunachalam</surname>
<given-names>PS</given-names>
</name>
<name>
<surname>Navarro</surname>
<given-names>M-J</given-names>
</name>
<name>
<surname>Tortorici</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Rogers</surname>
<given-names>K</given-names>
</name>
<name>
<surname>O’Connor</surname>
<given-names>MA</given-names>
</name>
<etal/>
</person-group>
<article-title>Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines</article-title>
<source>bioRxiv</source>
<year>2021b</year>
</element-citation>
</ref>
<ref id="R50">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>C</given-names>
</name>
<name>
<surname>van Haperen</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Gutiérrez-Álvarez</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Okba</surname>
<given-names>NMA</given-names>
</name>
<name>
<surname>Albulescu</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Widjaja</surname>
<given-names>I</given-names>
</name>
<name>
<surname>van Dieren</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Fernandez-Delgado</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Sola</surname>
<given-names>I</given-names>
</name>
<etal/>
</person-group>
<article-title>A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies</article-title>
<source>Nat Commun</source>
<year>2021</year>
<volume>12</volume>
<fpage>1715</fpage>
</element-citation>
</ref>
<ref id="R51">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wibmer</surname>
<given-names>CK</given-names>
</name>
<name>
<surname>Ayres</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Hermanus</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Madzivhandila</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kgagudi</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Oosthuysen</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Lambson</surname>
<given-names>BE</given-names>
</name>
<name>
<surname>de Oliveira</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Vermeulen</surname>
<given-names>M</given-names>
</name>
<name>
<surname>van der Berg</surname>
<given-names>K</given-names>
</name>
<etal/>
</person-group>
<article-title>SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma</article-title>
<source>Nat Med</source>
<year>2021</year>
<volume>27</volume>
<fpage>622</fpage>
<lpage>625</lpage>
</element-citation>
</ref>
<ref id="R52">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Winkler</surname>
<given-names>ES</given-names>
</name>
<name>
<surname>Gilchuk</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bailey</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Zost</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Jang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Allen</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Case</surname>
<given-names>JB</given-names>
</name>
<etal/>
</person-group>
<article-title>Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions and monocytes for optimal therapeutic protection</article-title>
<source>bioRxiv</source>
<year>2020</year>
<elocation-id>2020.12.28.424554</elocation-id>
</element-citation>
</ref>
<ref id="R53">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wrapp</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Corbett</surname>
<given-names>KS</given-names>
</name>
<name>
<surname>Goldsmith</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Hsieh</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Abiona</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Graham</surname>
<given-names>BS</given-names>
</name>
<name>
<surname>McLellan</surname>
<given-names>JS</given-names>
</name>
</person-group>
<article-title>Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation</article-title>
<source>Science</source>
<year>2020</year>
<volume>367</volume>
<fpage>1260</fpage>
<lpage>1263</lpage>
</element-citation>
</ref>
<ref id="R54">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ying</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Whitener</surname>
<given-names>B</given-names>
</name>
<name>
<surname>VanBlargan</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Hassan</surname>
<given-names>AO</given-names>
</name>
<name>
<surname>Shrihari</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>C-Y</given-names>
</name>
<name>
<surname>Karl</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Mackin</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Kafai</surname>
<given-names>NM</given-names>
</name>
<etal/>
</person-group>
<article-title>Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains</article-title>
<source>bioRxiv</source>
<year>2021</year>
</element-citation>
</ref>
<ref id="R55">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Beutler</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Shaabani</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>D</given-names>
</name>
<name>
<surname>He</surname>
<given-names>W-T</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Callaghan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Yong</surname>
<given-names>P</given-names>
</name>
<etal/>
</person-group>
<article-title>A protective broadly cross-reactive human antibody defines a conserved site of vulnerability on beta-coronavirus spikes</article-title>
<source>bioRxivorg</source>
<year>2021</year>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption>
<title>Repeated exposures to SARS-CoV-2 antigens through vaccination or infection enhance S-specific serum IgG and IgA binding titers.</title>
<p>
<bold>(A)</bold> Serum IgG binding titers at 30 or 60 days post infection or 10, 112, or 180 days post second or third vaccine dose were evaluated for longitudinal samples by ELISA using prefusion-stabilized SARS-CoV-2 S Hexapro as antigen. Serum samples were obtained from individuals who had a Delta breakthrough infection (n=15, magenta triangle), were previously infected then vaccinated (n=15, teal diamond), have only been vaccinated (n=15, orange circle), were infected in 2020 in Washington State (n=15, gray square), or were SARS-CoV-2 naive (samples taken prior to vaccination, n=15, open hexagon). <bold>(B)</bold> Serum IgA binding titers at 30 days post infection or 10 days post second vaccine dose were evaluated by ELISA using prefusion-stabilized SARS-CoV-2 S Hexapro as antigen. <bold>(C)</bold> Serum IgM binding titers at 30 days post infection or 10 days post second vaccine dose were evaluated by ELISA using prefusion-stabilized SARS-CoV-2 S Hexapro as antigen. <bold>(D)</bold> Serum IgG binding titers were evaluated by ELISA at 30 days post infection, 10 days post second or third vaccine dose or prior to SARS-CoV-2 exposure (SARS-CoV-2 naive) using prefusion-stabilized SARS-CoV 2P S as antigen. <bold>(E-F)</bold> Serum IgG binding titers were evaluated at 30 days post infection, 10 days post second or third vaccine dose, or prior to SARS-CoV-2 exposure (SARS-CoV-2 naive) by ELISA using OC43 S (E) or HKU1 2P S (F) as antigen. # of doses: number of vaccine doses received. Statistical significance was determined by Kruskal Wallis and Dunn’s multiple comparisons test and shown only when significant. <italic>*P</italic> &lt; 0.05; **<italic>P</italic> &lt; 0.01; ***<italic>P</italic> &lt; 0.001; and ****P &lt; 0.0001. LOD is shown as a gray horizontal dotted line when above the x axis. Raw fits are shown in <xref ref-type="supplementary-material" rid="SD1">Figure S1</xref> and <xref ref-type="supplementary-material" rid="SD1">S2</xref>.</p>
</caption>
<graphic xlink:href="EMS141105-f001"/>
</fig>
<fig id="F2" position="float">
<label>Figure 2</label>
<caption>
<title>Delta breakthrough, infected/vaccinated and triple vaccinated individuals have exceptionally high serum neutralizing activity.</title>
<p>Serum samples were obtained from individuals who had a Delta breakthrough infection (n=14, magenta triangle), who were previously infected then vaccinated (n=15, teal diamond, infected/vaccinated), who have been vaccinated only (n=15, orange circle), or who were infected only in 2020 in Washington State (n=15, gray square, HCS). All neutralization assays were performed using VeroE6-TMPRSS2 as target cells at least in duplicate. (<bold>A</bold>) SARS-CoV-2 G614 S VSV pseudotype neutralization. (<bold>B</bold>) SARS-CoV-2 Delta S VSV pseudotype neutralization. (<bold>C</bold>) SARS-CoV-2 Beta S VSV pseudotype neutralization. (<bold>D</bold>) SARS-CoV S VSV pseudotype neutralization. # of doses: number of vaccine doses received. Statistical significance was determined by Kruskal Wallis and Dunn’s multiple comparisons test and shown only within group or at matched timepoint for ease of viewing when significant. *<italic>P</italic> &lt; 0.05; **<italic>P</italic> &lt; 0.01; ***<italic>P</italic> &lt; 0.001; and ****P &lt; 0.0001. Normalized curves and fits are shown in <xref ref-type="supplementary-material" rid="SD1">Fig. S3-S13</xref>.</p>
</caption>
<graphic xlink:href="EMS141105-f002"/>
</fig>
</floats-group>
</article>
